Background and Objectives: Hospital readmissions serve as a significant negative prognostic indicator and have a considerable impact on healthcare utilization among individuals diagnosed with heart failure with preserved ejection fraction (HFpEF). For our study, we aimed to elucidate predictors and trends of HFpEF readmissions within a 30-day period. Methods: The Healthcare Cost and Utilization Project National Readmission Database (NRD) was queried between 2016–2020 to study the 30-day all-cause hospital readmission rate, predictors, duration of hospital stay, and the overall cost of hospitalization. Multivariate/univariate logistic and linear regression analysis were used to analyze the outcomes and adjust for possible confounders. Results: A total of 3,831,156 index hospitalizations for acute decompensated HFpEF were identified between the years 2016–2020, of which 673,844 (18.4%) patients were readmitted within 30 days. The 30-day all-cause readmissions increased significantly from 17.4% to 19.9% (p<0.001) in the 5-year trend analysis. The most common cardiovascular cause for readmission was hypertensive heart disease with chronic kidney disease stage 1–4 (13.2%). Independent predictors associated with increased rate of readmissions were patients that left against medical advice (adjusted odds ratio [aOR], 2.06; 95% confidence interval [CI], 1.99–2.14; p<0.001), cirrhosis (aOR, 1.33; 95% CI, 1.30–1.36; p<0.001), and chronic obstructive pulmonary disease (aOR, 1.27;95% CI, 1.25–1.29; p<0.001). Conclusions Nearly 1 in 5 patients with acute decompensated HFpEF were readmitted within 30 days (2016–2020), with readmissions rising over time. Identifying at-risk patients is crucial to reducing readmissions and costs.

BACKGROUND: Optimizing patients with advanced heart failure before orthotopic heart transplantation (OHT), especially in patients greater than 50 years old, is imperative to achieving successful post-transplant outcomes. Complications are well-described for patients bridged to transplant (BTT) with durable left ventricular assist device (LVAD) support. Given the lack of data available in older recipients after the recent increase in mechanical support use, we felt it crucial to report our center's one-year outcomes in older recipients after heart transplantation with percutaneously placed Impella 5.5 as a BTT. METHODS: Forty-nine OHT patients were supported with the Impella 5.5 intended as a bridge between December 2019 and October 2022 at Mayo Clinic in Florida. Data were extracted from the electronic health record at baseline and during their transplant episode of care after Institutional Review Boards approval as exempt for retrospective data collection. RESULTS: Thirty-eight patients aged 50 or older were supported with Impella 5.5 as BTT. Ten patients underwent heart and kidney transplantation within this cohort. The median age at OHT was 63 (58-68) years, with 32 male (84%) and six female patients (16%). Etiology was divided into ischemic (63%) and non-ischemic cardiomyopathy (37%). The baseline median ejection fraction was 19% (15-24). Most patients were in blood group O (60%), and 50% were diabetic. The average duration of support was 27 days (range 6-94). The median duration of follow-up is 488 days (185-693). For patients that have reached the 1-year follow-up timeframe (22 of 38, 58%), the 1-year post-transplant survival is 95%. CONCLUSION Our single-center data provides awareness for using the Impella 5.5 percutaneously placed axillary support device in older heart failure patients in cardiogenic shock as a bridge to transplantation. One-year survival outcomes after heart transplantation are excellent despite the older recipient's age and prolonged pre-transplant support.